このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

この研究では、感覚神経または混合運動神経の上肢神経裂傷を患っている人に神経修復製品であるNTX-001を使用した場合の有効性を評価します。

2026年10月2日 更新者:Neuraptive Therapeutics Inc.

外科的修復を必要とする上肢神経切断の治療における標準治療(神経断裂)と比較したNTX-001の安全性と有効性を評価する、多施設共同、無作為化、被験者および評価者を盲検化した第3相対照試験。

NTX-001 is a single use surgical product intended for use in conjunction with standard suture neurorrhaphy of severed nerves in patients between 18 and 80.

調査の概要

詳細な説明

NTX-001 has been developed as a surgical product to be used in conjunction with standard suture neurorrhaphy of a severed nerve. Use of NTX-001 is intended to safely accelerate the often slow and diminished return of function in repaired nerves. It often takes months and/or years to determine if function will be restored. By that point, restoration is often incomplete and can result in lifelong motor and/or sensory deficits. By reconnecting (PEG-fusion) a substantial number of axons within a severed nerve, the degeneration-regeneration cycle and subsequent atrophy may be reduced or even prevented for those axons and their targets, respectively. NTX-001 (PEG-fusion) has the potential to avoid the consequences of protracted denervation of distal target tissues by eliminating the period of total denervation thus reducing the time to stable recovery and providing greater innervation to affected tissues.

研究の種類

介入

入学 (推定)

98

段階

  • フェーズ 3

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究連絡先のバックアップ

研究場所

    • California
      • Los Angeles、California、アメリカ、90048
        • まだ募集していません
        • Cedars Sinai Medical Center
        • コンタクト:
        • コンタクト:
        • 主任研究者:
          • Meghan C McCullough, MD
      • San Francisco、California、アメリカ、94158
        • まだ募集していません
        • UCSF Health
        • コンタクト:
        • コンタクト:
    • Florida
      • Orlando、Florida、アメリカ、32806
      • Orlando、Florida、アメリカ、32804
        • 募集
        • Rothman Orthopedics - Advent Health
        • コンタクト:
        • コンタクト:
        • 主任研究者:
          • Amir Reza Kachooei, MD PhD
    • Georgia
      • Atlanta、Georgia、アメリカ、30303
        • 募集
        • Grady Health
        • コンタクト:
        • コンタクト:
        • 主任研究者:
          • Nicole A Zelenski, MD
    • Illinois
      • Chicago、Illinois、アメリカ、60637
        • 募集
        • University of Chicago
        • コンタクト:
        • コンタクト:
        • 主任研究者:
          • Jeffrey Stepan, MD
    • Kentucky
      • Louisville、Kentucky、アメリカ、40202
        • 募集
        • University of Louisville
        • コンタクト:
        • コンタクト:
        • 主任研究者:
          • Tuna Ozyurekoglu, MD
    • Louisiana
      • New Orleans、Louisiana、アメリカ、70112
        • 募集
        • Louisiana State University Health Sciences Center
        • 主任研究者:
          • Harvey Chim, MD, FACS
        • コンタクト:
        • コンタクト:
          • Tanja Milosavljevic, MSc, PhD
          • 電話番号:504-568-6876
          • メール:tmilos@lsuhsc.edu
    • Maryland
      • Baltimore、Maryland、アメリカ、21218
        • 募集
        • Curtis National Center at MedStar Union Memorial Hospital
        • コンタクト:
        • コンタクト:
        • 主任研究者:
          • Kenneth R Means Jr., MD
    • Missouri
      • Columbia、Missouri、アメリカ、65211
      • St Louis、Missouri、アメリカ、63110
        • 募集
        • Barnes-Jewish Hospital 1 Barnes Jewish Hospital Plaza St.
        • コンタクト:
        • 主任研究者:
          • David M Brogan, MD, MSc
        • コンタクト:
    • New Jersey
      • Camden、New Jersey、アメリカ、08103
        • 募集
        • The Cooper Health System
        • コンタクト:
        • コンタクト:
        • 主任研究者:
          • David A Fuller, MD
    • New York
      • New York、New York、アメリカ、10003
    • Ohio
      • Cincinnati、Ohio、アメリカ、45267
        • 募集
        • UC Health
        • 主任研究者:
          • Sonu Jain, MD
        • コンタクト:
        • コンタクト:
          • Brittany Rowley, CCRC Clinical Research Professional III
          • 電話番号:513-558-2765
          • メール:rowleybm@ucmail.uc.edu
      • Cincinnati、Ohio、アメリカ、45267
        • 募集
        • University of Cincinnati Health
        • 主任研究者:
          • Sonu Jain, MD
        • コンタクト:
        • コンタクト:
      • Cleveland、Ohio、アメリカ、44109
        • 募集
        • The MetroHealth System
        • コンタクト:
        • コンタクト:
        • 主任研究者:
          • Kyle Chepla, MD
      • Columbus、Ohio、アメリカ、43212
        • 募集
        • The Ohio State University Wexner Medical Center
        • コンタクト:
        • コンタクト:
        • 主任研究者:
          • Ryan Schmucker, MD
    • Pennsylvania
      • Philadelphia、Pennsylvania、アメリカ、19104
        • 募集
        • University of Pennsylvania, Department of Orthopaedic Surgery
        • コンタクト:
        • コンタクト:
        • 主任研究者:
          • Ines C Lin, MD
      • Pittsburgh、Pennsylvania、アメリカ、15212
        • 募集
        • Allegheny Health Network
        • コンタクト:
        • コンタクト:
          • Mary Fetter - Lead Clinical Research Coordinator
          • 電話番号:412-359-8292
          • メール:Mary.Fetter@ahn.org
        • 主任研究者:
          • Steven Regal, MD
    • South Carolina
      • Charleston、South Carolina、アメリカ、29429
        • 募集
        • Medical University of South Carolina
        • コンタクト:
        • コンタクト:
          • Charles A Daly, MD
          • 電話番号:843-876-2211
          • メール:dalyc@musc.edu
        • 主任研究者:
          • Charles Daly, MD
    • Texas
      • Dallas、Texas、アメリカ、75246
        • 募集
        • Baylor, Scott and White Health
        • コンタクト:
        • コンタクト:
        • 主任研究者:
          • Asadullah Helal, MD
      • Lubbock、Texas、アメリカ、79415
        • 募集
        • Texas Tech
        • 主任研究者:
          • Brendan MacKay, MD
        • コンタクト:
        • コンタクト:
    • Utah
      • Salt Lake City、Utah、アメリカ、84132
        • 募集
        • University of Utah Health
        • コンタクト:
        • コンタクト:
        • 主任研究者:
          • Mark Mahan, MD, FAANS
    • Virginia
      • Charlottesville、Virginia、アメリカ、22903
        • 募集
        • UVA Health
        • コンタクト:
        • コンタクト:
        • 主任研究者:
          • Brett DeGeorge, MD
    • Washington
      • Seattle、Washington、アメリカ、98104
        • 募集
        • Harborview Medical Center
        • コンタクト:
          • Laura Hennessy, RN
          • 電話番号:206-744-7723
          • メール:hennessy@uw.edu
        • コンタクト:
          • Yusha ( Katie) Liu, MD PhD
          • 電話番号:206-744-3000
          • メール:HMCnerve@uw.edu
        • 主任研究者:
          • Katie Liu, MD

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

18年~80年 (大人、高齢者)

健康ボランティアの受け入れ

いいえ

受講資格のある性別

全て

説明

Inclusion Criteria:

  • The subject has voluntarily agreed to participate in this study and has signed an Institutional Review Board (IRB) approved informed consent form.
  • The subject is between eighteen (18) and eighty (80) years of age.
  • The subject has clinical evidence of a Sunderland's 4th degree (Class II) or 5th degree (Class III) nerve transection(s) that has resulted in upper extremity nerve impairment that requires surgical treatment.

Exclusion Criteria:

  • Subjects whose nerve repair will occur greater than 48 hours after nerve transection.
  • Subjects requiring nerve repair involving an autograft, allograft or conduit(s).
  • Subjects with multiple transected nerve injuries are allowed into the study only if all injuries are amenable to direct repair.
  • Subjects who, in the judgement of the investigator, are not likely to demonstrate meaningful recovery within a reasonable time frame during follow up due to significant muscle atrophy or other morbidity.
  • The subject's injury is a result of a suicide attempt or self- harm.
  • The subject has documented history or clinical signs of any condition where NTX-001 might not prove beneficial (e.g., systemic neuromuscular disease, systemic neurological deficit, or other treatments known to affect the growth and/or physiology of the neural and vascular system).
  • The subject has a known allergy to polyethylene glycol (PEG) or human grade silicone.
  • The subject is pregnant or breastfeeding.
  • The subject is currently enrolled in another investigational study or has participated in an investigational study within 30 days prior to screening.

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:処理
  • 割り当て:ランダム化
  • 介入モデル:並列代入
  • マスキング:トリプル

武器と介入

参加者グループ / アーム
介入・治療
実験的:NTX-001

NTX-001 used during the surgical repair of an upper extremity peripheral nerve injury in conjunction with standard suture neurorrhaphy.

One time use surgical product, 3 solutions applied topically, in sequence, to the peripheral nerve repair site, in conjunction with standard suture neurorrhaphy.

介入なし:Standard Suture Neurorrhaphy

Standard of Care

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Mean Michigan Hand Questionnaire (MHQ) Two Domain Score (ADL and Pain)
時間枠:Screening Visit, Week 24

The subject will complete the MHQ questionnaire at Weeks 2, 4, 6, 8, 10, 12, 16, 20, 24, 30, 36, 42, and 48. A measure of the mean of MHQ in the Two Domains, Activities of Daily Living and Pain Scores, at Week 24 in the NTX-001 group as compared to Standard of Care (SoC). In the ADL subdomain, a higher component score indicates better function. In the Pain subdomain, a higher component score indicates greater pain. A total MHQ score of 100 is considered the best functional score.

Screening Visit, Week 24
Safety - Columbia-Suicide Severity Rating Scale
時間枠:Screening Visit, Weeks 4, 12, and 48

The Columbia-Suicide Severity Rating Scale (C-SSRS) is a suicide risk assessment tool. The C-SSRS tool asks; whether and when the subject has had a thought about suicide (ideation); what actions they might have taken and what they did to prepare for suicide; whether and when they attempted suicide or began a suicide attempt that was either interrupted by another person or stopped of their own volition. The answers identify whether someone is at risk for suicide, assessing the severity and immediacy of that risk, and gauging the level of support that the person needs. The first assessment is done by study staff at screening. Subsequent assessments will be completed by the subject at Weeks 4, 12, and 48. A score of 0 indicates no risk, 1-2 indicates low risk, and 3+ indicates moderate to high risk.

Screening Visit, Weeks 4, 12, and 48

二次結果の測定

結果測定
メジャーの説明
時間枠
Intraoperative CheckPoint® Stimulation.
時間枠:In Operating Room

A CheckPoint® Stimulator will be used intra-operatively to detect immediate reconnection of severed peripheral nerves (axons) in mixed-motor nerves only. The measures include in response of direct nerve stimulation, proximally and distally to suture site.

In Operating Room
MHQ Total Score
時間枠:Screening Visit; Weeks 2, 4, 6, 8, 10, 12, 16, 20, 24, 30, 36, 42, and 48

The MHQ quantifies different impairments between the subjects in uninjured and involved upper extremities. A general survey of hand function includes twenty-five items for the right and the left hand, as well as questions for both hands. Questions regarding function specifically refer to the impact of the involved hand and/or wrist on the activity which presumably takes all joints of the upper extremity into account. The overall questionnaire is scored from 0 to 100, with 100 being the optimal score.

Screening Visit; Weeks 2, 4, 6, 8, 10, 12, 16, 20, 24, 30, 36, 42, and 48
Time to Return to Function
時間枠:Screening Visit, Weeks 2, 4, 6, 8, 10, 12, 16, 20, 24, 30, 36, 42, and 48.

Achievement of seventy-five (75)% function in the combined ADL and pain MHQ domain scores. The Activities of Daily Living component evaluates the ability to perform specific tasks using either hand or both hands together. The Pain subdomain addresses the frequency and intensity of pain in both the right and left hands/wrists, along with its impact on sleep and daily activities, and the emotional distress it causes. The overall questionnaire is scored from 0 to 100, with 100 being the optimal score.

Screening Visit, Weeks 2, 4, 6, 8, 10, 12, 16, 20, 24, 30, 36, 42, and 48.
Change in NPRS
時間枠:Screening Visit, Weeks 2, 4, 6, 8, 10, 12,16, 20, 24, 30, 36, 42, and 48

The NPRS is used to assess for pain and to determine pain intensity. The NPRS is an 11-point scale scored from 0-10: 1) "0" = no pain 2) "10" = the most intense pain imaginable. The average of the 3 ratings is used to represent the subject's level of pain over the previous 24 hours.

Screening Visit, Weeks 2, 4, 6, 8, 10, 12,16, 20, 24, 30, 36, 42, and 48
Semmes Weinstein Monofilament Test (SWMT)
時間枠:Weeks 2, 4, 8, 12, 24, 36, 48.

SWMT provides information on protective sensation, the rigorous system can detect relatively minor differences in sensory function, and changes will occur early in nerve injury. The assessment tool consists of a set of monofilaments that vary in thickness and diameter, the gradient forces of these monofilaments that subjects' can feel, range from 0.086 gm to 0.448gm. The normal value in the hand is in the range of the green filament (1.65 to 2.83 mN).

Weeks 2, 4, 8, 12, 24, 36, 48.
MHQ Two Domain Score
時間枠:Screening Visit; Weeks 2, 4, 6, 8, 10, 12, 16, 20, 30, 36, 42, 48

The Activities of Daily Living component evaluates the ability to perform specific tasks using either hand or both hands together. The Pain subdomain addresses the frequency and intensity of pain in both the right and left hands/wrists, along with its impact on sleep and daily activities, and the emotional distress it causes. The raw scale score for each of the 6 scales is the sum of the responses of each scale item. The raw score is converted to a score range from 0 to 100. 100 being the best.

Screening Visit; Weeks 2, 4, 6, 8, 10, 12, 16, 20, 30, 36, 42, 48
Change from Week 2 in MHQ Two Domain Score
時間枠:Weeks 2, 4, 6, 8, 10, 12, 16, 20, 24, 30, 36, 42, and 48.

The Activities of Daily Living component evaluates the ability to perform specific tasks using either hand or both hands together. The Pain subdomain addresses the frequency and intensity of pain in both the right and left hands/wrists, along with its impact on sleep and daily activities, and the emotional distress it causes. The raw scale score for each of the 6 scales is the sum of the responses of each scale item. The raw score is converted to a score range from 0 to 100. 100 being the best.

Weeks 2, 4, 6, 8, 10, 12, 16, 20, 24, 30, 36, 42, and 48.
Medical Research Council Classification (MRCC) Sensory Score
時間枠:Weeks 2, 4, 8, 12, 24, 36, and 48.

The scale is commonly used including 2 Point Discrimination for grading the sensory outcome after peripheral nerve surgery. This scale is categorized into S0-S4: S0 is the absence of sensibility; S1 is the recovery of deep cutaneous pain; S2 is the return of superficial cutaneous pain and some degree of tactile sensibility; S3 is the return of superficial cutaneous pain and tactile sensibility without over response; and S4 is the complete recovery.

Weeks 2, 4, 8, 12, 24, 36, and 48.
Medical Research Council Classification (MRCC) Motor Score
時間枠:Weeks 2, 4, 8, 12, 24, 36, 48

This assessment is conducted on mixed motor nerve injuries only. Strength can best be assessed by isolating an individual muscle group and comparing power with that of the subject. It can be conducted to assess larger muscles or muscle groups as well as intrinsic muscles of the hand. Measuring the difference between the affected limb and the contralateral limb. 0/5 is no muscle activation whatsoever; 1/5 is muscle activation without limb movement; 2/5 implies that the limb can be moved only when gravity is taken out of the equation; 3/5 means that the subject can overcome gravity but not resistance;• 4/5 (or 4+ or 4-) implies weakness with enough strength to overcome varying degrees of physical resistance; 5/5 is full strength.

Weeks 2, 4, 8, 12, 24, 36, 48
Change from Baseline (W2) in Numeric Pain Rating Scale (NPRS)
時間枠:Weeks 2, 24.

The NPRS is used to assess for pain and to determine pain intensity. The NPRS is an 11-point scale scored from 0-10: 1) "0" = no pain 2) "10" = the most intense pain imaginable. The average of the 3 ratings is used to represent the subject's level of pain over the previous 24 hours.

Weeks 2, 24.
Patient Global Impression of Change Score
時間枠:Weeks 2, 4, 6, 8, 10, 12, 16, 20, 30, 36, 42, and 48

This scale evaluates all aspects of patients; health and assesses if there has been an improvement or decline in clinical status. PGIC is a 7-point scale depicting a subjects rating of overall improvement. The subject rates their change as "very much improved," "much improved," "minimally improved," "no change," "minimally worse," "much worse," or "very much worse."

Weeks 2, 4, 6, 8, 10, 12, 16, 20, 30, 36, 42, and 48
Change in Total MHQ Score
時間枠:Screening Visit; Weeks 2, 4, 6, 8, 10, 12, 16, 20, 24, 30, 36, 42, and 48.

The MHQ quantifies different impairments between the subjects uninjured and involved upper extremities. It was designed as a general survey of hand function and includes twenty-five items for the right and the left hand, as well as questions for both hands. Furthermore, questions regarding function specifically refer to the impact of the involved hand and/or wrist on the activity which presumably takes all joints of the upper extremity into account. The overall questionnaire is scored from 0 to 100, with 100 being the optimal score.

Screening Visit; Weeks 2, 4, 6, 8, 10, 12, 16, 20, 24, 30, 36, 42, and 48.
Change from Baseline in Patient Global Impression of Severity Score (PGIS)
時間枠:Screening Visit; Weeks 2, 4, 6, 8, 10, 12, 16, 20, 24, 30, 36, 42 and 48.

The PGIS is a single question asking the subject to rate the severity of the injury from the last visit. PGIS is a scale depicting a subject's rating of overall severity. The subject scores their perception of severity as "none," "mild," "moderate," "severe," or "very severe."

Screening Visit; Weeks 2, 4, 6, 8, 10, 12, 16, 20, 24, 30, 36, 42 and 48.

その他の成果指標

結果測定
メジャーの説明
時間枠
Electromyography (EMG) Testing
時間枠:Weeks 12, 24.

EMG will be used to detect reconnection of severed peripheral nerves (axons) using PEG Fusion. Restoration of nerve conduction indicates the restoration of axon continuity, which is a prerequisite for the prevention of Wallerian degeneration, neuromuscular junction degeneration, muscle atrophy and functional recovery. This testing will be done at select clinical sites.

Weeks 12, 24.
Nerve Conduction Velocity (NCV)
時間枠:Weeks 12, 24

NVC testing measures how fast an electrical impulse moves through a nerve. This testing will be done at select clinical sites.

Weeks 12, 24
Physical and Occupational Therapy
時間枠:Weeks 2, 4, 8, 12, 24, 36, and 48.

Each subject will have the number of times physical therapy and/or occupational therapy is prescribed to determine if this activity affects the sensory and functional outcomes of the nerve repair between NTX-001 and SOC.

Weeks 2, 4, 8, 12, 24, 36, and 48.

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

捜査官

  • スタディディレクター:Seth Schulman, MD、Neuraptive Therapeutics Inc.

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

便利なリンク

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (実際)

2025年2月10日

一次修了 (推定)

2027年3月31日

研究の完了 (推定)

2027年4月30日

試験登録日

最初に提出

2024年9月24日

QC基準を満たした最初の提出物

2024年9月24日

最初の投稿 (実際)

2024年9月27日

学習記録の更新

投稿された最後の更新 (実際)

2026年10月6日

QC基準を満たした最後の更新が送信されました

2026年10月2日

最終確認日

2026年5月1日

詳しくは

本研究に関する用語

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

はい

米国FDA規制機器製品の研究

はい

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する